27 active not recruiting, 16 recruiting, 6 completed, 6 withdrawn. 33 Phase 2, 23 Phase 1, 8 Phase 3, 5 Not applicable, 3 Early Phase 1.
Follow X-Ray Imaging: new trials by email Literature Review of X-Ray Imaging trials Research Report on X-Ray Imaging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients Dietary Fiber, Enema Administration, Loperamide Hydrochloride - Low Anterior Resection Syndrome, Rectal Carcinoma | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 80 | 2027-02-15 | 2026-10-06 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy Biospecimen Collection, Computed Tomography, Leukapheresis - Myxoid Liposarcoma, Round Cell Liposarcoma | Early Phase 1 | Recruiting | Seth Pollack | 8 | 2026-04-13 | 2026-08-27 |
| Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection - Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-12-30 | 2026-04-27 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-08-04 | 2025-07-03 | |
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Recruiting | Jochen Lorch | 33 | 2025-06-06 | 2026-06-26 |
| CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2025-05-23 | 2026-10-30 |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) Bone Scan, Carboplatin, Computed Tomography - Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor | Phase 3 | Recruiting | Children's Oncology Group | 1656 | 2025-04-15 | 2026-08-25 |
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Bendamustine, Biopsy, Biospecimen Collection - Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-15 | 2025-04-01 | |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) Biopsy Procedure, Biospecimen Collection, Chest Radiography - Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2024-06-25 | 2026-10-14 |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 16 | 2024-04-11 | 2026-08-17 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Abdullah Khan | 12 | 2023-12-21 | 2026-05-13 |
Showing 20 of 64. Sign in to see all of them.
Wilms Tumor (8) · Glioma (7) · Hepatoblastoma (7) · Lymphoma, Non-Hodgkin (7) · Medulloblastoma (7) · Neuroblastoma (7) · Osteosarcoma (7) · Rhabdoid Tumor (7) · Central Nervous System Neoplasms (6) · Ependymoma (6) · Histiocytosis, Langerhans-Cell (6) · Neuroectodermal Tumors, Primitive, Peripheral (6) · Rhabdomyosarcoma (6) · Sarcoma (6) · Multiple Myeloma (5)
National Cancer Institute (NCI) (29) · Fred Hutchinson Cancer Center (8) · Children's Oncology Group (6) · City of Hope Medical Center (4) · Mayo Clinic (4) · Northwestern University (2) · Abdullah Khan (1) · GE Healthcare (1) · Jochen Lorch (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Naresh Bumma (1) · Ohio State University Comprehensive Cancer Center (1) · Ottawa Hospital Research Institute (1)
United States (60) · Canada (16) · Puerto Rico (12) · Australia (10) · New Zealand (5) · Israel (2) · Saudi Arabia (2) · Belgium (1)
Jordan Gauthier (2) · Timothy A Yap (2) · Abdullah M Khan, MBBS, MSc (1) · Alessandra C Gasior, DO (1) · Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Alice Lee (1) · Amandeep Salhotra (1) · Amit J Sabnis (1) · Andrea T Franson (1) · Anjali S Advani (1) · Chaoyuan Kuang (1) · Christine D Berg (1) · Donald W Parsons (1) · Dwight H Owen (1)
PMID 31401903, PMID 32589970, PMID 33152282, PMID 33277073, PMID 33370024, PMID 33591402, PMID 34340209, PMID 34486544, PMID 34548240, PMID 35353553, PMID 35658861, PMID 36322825, PMID 37222189, PMID 37598723, PMID 38131628, PMID 38497709, PMID 38741776, PMID 39047240, PMID 39282913, PMID 40226119, PMID 40902132, PMID 40966692, PMID 41166674, PMID 41261199, PMID 41524552, PMID 42456089, PMID 42686334, PMID 42832396, PMID 42867148
U10CA180886 (12), P30CA033572 (4), P30CA060553 (4), U10CA180868 (3), UM1CA186688 (3), UM1CA228823 (3), U10CA180820 (2), U10CA180821 (2), U10CA180830 (2), U10CA180888 (2), UM1CA081457 (2), UM1CA186690 (2), UM1CA186712 (2), P01CA078902 (1), P30CA015704 (1)